Phase 3 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years of age
- People who have been diagnosed with atrial fibrillation (an irregular heart rhythm) confirmed by a heart tracing (ECG) before their cardioversion procedure
- People whose heart was successfully returned to a normal rhythm during cardioversion, and stayed in normal rhythm for at least 30 minutes afterwards
- People who are able to give written consent to participate
Who may not be able to join:
- People whose heart did not return to normal rhythm during cardioversion, or whose irregular rhythm came back within 30 minutes of the procedure
- People who had a heart rhythm problem other than atrial fibrillation before their cardioversion
- People who had a pulmonary vein isolation procedure (a type of heart procedure) within the 3 months before cardioversion, or who have one planned within 3 months after
- People who have a known intolerance or allergic reaction to the medication Colchicine
- People who are already taking Colchicine for another medical reason
- People who are currently taking certain medications that strongly affect how the body processes drugs, including clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole, or itraconazole
- People who have serious digestive system problems, such as severe stomach inflammation or persistent diarrhoea
- People who have a significant liver condition that is causing noticeable symptoms
- People who have severe kidney disease (confirm with trial site for specific kidney function measurement)
- People who have a significant disorder affecting their blood cells (for example, certain bone marrow conditions)
- People who have a seriously weakened immune system, for example due to an organ transplant or certain autoimmune conditions
- Women who are pregnant, breastfeeding, or who could become pregnant and are not using a highly effective form of contraception
- People who are not expected to live longer than one year
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philipp Krisai, PD Dr. med., University Hospital, Basel, Switzerland
Phone: +41 61 265 25 25
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of atrial fibrillation (AF) recurrence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.